查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703394

頭孢呋辛市場－全球產業規模、佔有率、趨勢、機會和預測，按銷售管道、等級、最終用途、地區和競爭細分，2020-2030 年

Cefuroxime Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By Grade, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球頭孢呋辛市場價值為 5.3088 億美元，預計到 2030 年將達到 8.4401 億美元，預測期內年複合成長率(CAGR) 為 5.10%。市場正在經歷中等但持續的成長，主要受頭孢呋辛的廣譜抗菌特性以及對呼吸道和泌尿道感染有效治療的需求不斷成長的推動。

市場概覽
預測期 2026-2030
2024年市場規模 5.3088億美元
2030年市場規模 8.4401億美元
2025-2030 年複合年成長率 5.10%
成長最快的領域 直接的
最大的市場 亞太

頭孢呋辛作為第二代頭孢菌素抗生素，因其對革蘭氏陽性菌和革蘭氏陰性菌均有效而被廣泛使用。它常用於治療支氣管炎、鼻竇炎、肺炎、中耳炎和各種皮膚感染等疾病，在全球抗菌治療中發揮著至關重要的作用。

傳染病發病率的上升進一步推動了市場的成長，特別是在醫療基礎設施正在快速轉型的發展中地區。

關鍵市場促進因素

全球醫療保健產業的擴張

主要市場挑戰

抗生素抗藥性不斷上升

主要市場趨勢

細菌感染發生率上升

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球頭孢呋辛市場的影響

第5章：全球頭孢呋辛市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 按等級（Axetil，鈉）
    • 依最終用途（支氣管炎、淋病、萊姆病、皮膚感染、耳部感染、咽喉感染等）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美頭孢呋辛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲頭孢呋辛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太頭孢呋辛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美頭孢呋辛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲頭孢呋辛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球頭孢呋辛市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • Zhuhai United Laboratories Co.
  • Nectar Lifesciences Ltd.
  • Dhanuka Laboratories Pvt Ltd
  • Aurobindo Pharma Limited
  • Covalent laboratories private limited
  • Orchid Pharma
  • Akums drugs & pharmaceuticals ltd
  • Lupin Limited
  • Hetero Labs Ltd

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28276

Global Cefuroxime market was valued at USD 530.88 million in 2024 and is projected to reach USD 844.01 million by 2030, growing at a compound annual growth rate (CAGR) of 5.10% during the forecast period. The market is witnessing moderate yet consistent growth, primarily driven by Cefuroxime's broad-spectrum antibacterial properties and the rising need for effective treatments for respiratory and urinary tract infections.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 530.88 Million
Market Size 2030USD 844.01 Million
CAGR 2025-20305.10%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

As a second-generation cephalosporin antibiotic, Cefuroxime is widely prescribed due to its efficacy against both Gram-positive and Gram-negative bacteria. It is commonly utilized in the treatment of conditions such as bronchitis, sinusitis, pneumonia, otitis media, and various skin infections, thereby playing a vital role in global antimicrobial therapy.

Market growth is further fueled by the increasing incidence of infectious diseases, particularly in developing regions where healthcare infrastructure is undergoing rapid transformation.

Key Market Drivers

Expansion of the Global Healthcare Sector

The ongoing growth of the global healthcare industry significantly contributes to the Cefuroxime market's expansion. The hospital segment alone accounted for approximately 40% of the global healthcare market in 2022, with a value exceeding USD 3.9 trillion. This figure is expected to rise to 44% by 2029, reaching a projected market size of USD 5.19 trillion. As hospitals increasingly become central to healthcare delivery, the demand for broad-spectrum antibiotics such as Cefuroxime continues to grow in tandem with healthcare infrastructure improvements, enhanced access to medical services, and evolving treatment protocols.

Cefuroxime is widely utilized in the management of a broad range of bacterial infections, including respiratory tract infections, skin infections, urinary tract infections, and for surgical prophylaxis. As such, it remains an indispensable part of modern antimicrobial therapy.

Key Market Challenges

Rising Antibiotic Resistance

One of the most significant challenges facing the global Cefuroxime market is the increasing prevalence of antibiotic resistance, which is undermining the effectiveness of many broad-spectrum antibiotics, including second-generation cephalosporins. As bacterial strains develop mechanisms to resist antibiotic treatment, the therapeutic reliability of Cefuroxime is being compromised in certain indications.

This trend has led to a more cautious approach to antibiotic prescribing, in alignment with international antimicrobial stewardship efforts, potentially reducing prescription volumes in favor of newer, more targeted therapies. The emergence of multidrug-resistant bacteria presents a growing threat to public health, highlighting the need for innovation in antibiotic development. As an established molecule, Cefuroxime faces limitations in this evolving landscape, presenting both clinical and commercial challenges for pharmaceutical companies striving to balance responsible antibiotic use with sustained product viability.

Key Market Trends

Increasing Incidence of Bacterial Infections

The global rise in bacterial infections represents a key trend shaping the Cefuroxime market's growth trajectory. Bacterial infections are responsible for approximately 7.7 million deaths annually, accounting for one in every eight fatalities and ranking as the second leading cause of death worldwide. Alarmingly, nearly 5 million of these deaths are linked to antibiotic-resistant bacterial strains, highlighting the critical threat posed by antimicrobial resistance.

This escalating public health issue has driven heightened demand for broad-spectrum antibiotics like Cefuroxime, particularly in healthcare settings managing high incidences of respiratory, urinary tract, and skin and soft tissue infections. As a result, Cefuroxime continues to play a vital role in both inpatient and outpatient antimicrobial treatment strategies.

Key Market Players

  • Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • Zhuhai United Laboratories Co.
  • Nectar Lifesciences Ltd.
  • Dhanuka Laboratories Pvt Ltd
  • Aurobindo Pharma Limited
  • Covalent laboratories private limited
  • Orchid Pharma
  • Akums drugs & pharmaceuticals ltd
  • Lupin Limited
  • Hetero Labs Ltd

Report Scope

In this report, the Global Cefuroxime Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefuroxime Market, By Sales Channel:

  • Direct
  • Indirect

Cefuroxime Market, By Grade:

  • Axetil
  • Sodium

Cefuroxime Market, By End Use:

  • Bronchitis
  • Gonorrhea
  • Lyme Disease
  • Skin Infection
  • Ear Infection
  • Throat Infection
  • Others

Cefuroxime Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefuroxime Market.

Available Customizations:

Global Cefuroxime Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefuroxime Market

5. Global Cefuroxime Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By Grade (Axetil, Sodium)
    • 5.2.3. By End Use (Bronchitis, Gonorrhea, Lyme Disease, Skin Infection, Ear Infection, Throat Infection, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Cefuroxime Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By Grade
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cefuroxime Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By Grade
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico Cefuroxime Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By Grade
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada Cefuroxime Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By Grade
        • 6.3.3.2.3. By End Use

7. Europe Cefuroxime Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By Grade
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cefuroxime Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By Grade
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany Cefuroxime Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By Grade
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Cefuroxime Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By Grade
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Cefuroxime Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By Grade
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Cefuroxime Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By Grade
        • 7.3.5.2.3. By End Use

8. Asia Pacific Cefuroxime Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By Grade
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cefuroxime Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By Grade
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Cefuroxime Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By Grade
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea Cefuroxime Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By Grade
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan Cefuroxime Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By Grade
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Cefuroxime Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By Grade
        • 8.3.5.2.3. By End Use

9. South America Cefuroxime Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By Grade
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cefuroxime Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By Grade
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina Cefuroxime Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By Grade
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia Cefuroxime Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By Grade
        • 9.3.3.2.3. By End Use

10. Middle East and Africa Cefuroxime Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By Grade
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cefuroxime Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By Grade
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia Cefuroxime Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By Grade
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE Cefuroxime Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By Grade
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cefuroxime Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Anhui BBAC Likang Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Zhuhai United Laboratories Co.
  • 15.3. Nectar Lifesciences Ltd.
  • 15.4. Dhanuka Laboratories Pvt Ltd
  • 15.5. Aurobindo Pharma Limited
  • 15.6. Covalent laboratories private limited
  • 15.7. Orchid Pharma
  • 15.8. Akums drugs & pharmaceuticals ltd
  • 15.9. Lupin Limited
  • 15.10. Hetero Labs Ltd

16. Strategic Recommendations

17. About Us & Disclaimer